Utility of Hyperbaric Oxygen in Treatment of Bisphosphonate-Related Osteonecrosis of the Jaws

Journal of Oral and Maxillofacial Surgery

Volumn 67, Issue 5 SUPPL., 2009, Pages 96-106

  Freiberger, John J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID;

ANTIBIOTIC THERAPY; ARTICLE; BONE TURNOVER; HUMAN; HYPERBARIC OXYGEN; JAW OSTEONECROSIS; OSTEOCLAST; RISK ASSESSMENT; WOUND HEALING;

ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; GROWTH SUBSTANCES; HUMANS; HYPERBARIC OXYGENATION; JAW DISEASES; OSTEOCLASTS; OSTEONECROSIS; OXYGEN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 64249147273     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2008.12.003     Document Type: Article

References (96)

1. Feldmeier J.J. Hyperbaric oxygen 2003: Indications and Results-Hyperbaric Oxygen Therapy Committee Report (June 2003) (2003), Undersea and Hyperbaric Medical Society, Kensington, MD
2. Mainous E.G., and Hart G.B. Osteoradionecrosis of the mandible: Treatment with hyperbaric oxygen. Arch Otolaryngol 101 (1975) 173
3. Marx R.E. A new concept in the treatment of osteoradionecrosis. J Oral Maxillofac Surg 41 (1983) 351
4. Marx R.E. Osteoradionecrosis: A new concept of its pathophysiology. J Oral Maxillofac Surg 41 (1983) 283
5. Knighton D.R., Halliday B., and Hunt T.K. Oxygen as an antibiotic: The effect of inspired oxygen on infection. Arch Surg 119 (1984) 199
6. Knighton D.R., Fiegel V.D., Halverson T., et al. Oxygen as an antibiotic. The effect of inspired oxygen on bacterial clearance. Arch Surg 125 (1990) 97
7. Elayan I.M., Axley M.J., Prasad P.V., et al. Effect of hyperbaric oxygen treatment on nitric oxide and oxygen free radicals in rat brain. J Neurophysiol 83 (2000) 2022
8. Tandara A.A., and Mustoe T.A. Oxygen in wound healing-More than a nutrient. World J Surg 28 (2004) 294
9. Boykin Jr. J.V., and Baylis C. Hyperbaric oxygen therapy mediates increased nitric oxide production associated with wound healing: A preliminary study. Adv Skin Wound Care 20 (2007) 382
10. Thom S.R., Bhopale V.M., Velazquez O.C., et al. Stem cell mobilization by hyperbaric oxygen. Am J Physiol Heart Circ Physiol 290 (2006) H1378
11. Asano T., Kaneko E., Shinozaki S., et al. Hyperbaric oxygen induces basic fibroblast growth factor and hepatocyte growth factor expression, and enhances blood perfusion and muscle regeneration in mouse ischemic hind limbs. Circ J 71 (2007) 405
12. Gallagher K.A., Goldstein L.J., Thom S.R., et al. Hyperbaric oxygen and bone marrow-derived endothelial progenitor cells in diabetic wound healing. Vascular 14 (2006) 328
13. Gutsaeva D.R., Suliman H.B., Carraway M.S., et al. Oxygen-induced mitochondrial biogenesis in the rat hippocampus. Neuroscience 137 (2006) 493
14. Cabigas B.P., Su J., Hutchins W., et al. Hyperoxic and hyperbaric-induced cardioprotection: Role of nitric oxide synthase 3. Cardiovasc Res 72 (2006) 143
15. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479
16. Bedogni A., Blandamura S., Lokmic Z., et al. Bisphosphonate-associated jawbone osteonecrosis: A correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105 (2008) 358
17. Khosa A.D., Nayyar M.S., and Beirne J.C. Osteochemonecrosis of jaws and bisphosphonates. Ir Med J 100 (2007) 410
18. Tolar J., Teitelbaum S.L., and Orchard P.J. Osteopetrosis. N Engl J Med 351 (2004) 2839
19. Lee N.K., Choi Y.G., Baik J.Y., et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106 (2005) 852
20. Ha H., Kwak H.B., Lee S.W., et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 301 (2004) 119
21. Bai X.C., Lu D., Liu A.L., et al. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J Biol Chem 280 (2005) 17497
22. Hayman A.R., Jones S.J., Boyde A., et al. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development (Cambridge, England) 122 (1996) 3151
23. Freiberger J.J., Padilla-Burgos R., Chhoeu A.H., et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: A case series. J Oral Maxillofac Surg 65 (2007) 1321
24. Rodan G.A., and Reszka A.A. Bisphosphonate mechanism of action. Curr Mol Med 2 (2002) 571
25. Gutta R., and Louis P.J. Bisphosphonates and osteonecrosis of the jaws: Science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 (2007) 186
26. Matsuo K., and Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 473 (2008) 201
27. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat Rev 4 (2003) 638
28. Glantschnig H., Fisher J.E., Wesolowski G., et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 10 (2003) 1165
29. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., et al. Further insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61 (2002) 1255
30. Roelofs A.J., Thompson K., Gordon S., et al. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res 12 20 Pt 2 (2006) 6222s
31. Benford H.L., Frith J.C., Auriola S., et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56 (1999) 131
32. Dunford J.E., Thompson K., Coxon F.P., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296 (2001) 235
33. Coxon F.P., Thompson K., and Rogers M.J. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6 (2006) 307
34. Coxon F.P., Benford H.L., Russell R.G., et al. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 54 (1998) 631
35. Monkkonen H., Auriola S., Lehenkari P., et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 147 (2006) 437
36. Kellinsalmi M., Monkkonen H., Monkkonen J., et al. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 97 (2005) 382
37. Van den Wyngaert T., Huizing M.T., and Vermorken J.B. Bisphosphonates and osteonecrosis of the jaw: Cause and effect or a post hoc fallacy?. Ann Oncol 17 (2006) 1197
38. Grotz K.A., Walter C., Kuttner C., et al. [Relevance of bisphosphonate long-term therapy in radiation therapy of endosteal jaw metastases]. Strahlenther Onkol 183 (2007) 190
39. Cartsos V.M., Zhu S., and Zavras A.I. Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people. J Am Dent Assoc 139 (2008) 23
40. Wilkinson G.S., Kuo Y.F., Freeman J.L., et al. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst 99 (2007) 1016
41. Khamaisi M., Regev E., Yarom N., et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92 (2007) 1172
42. Sarasquete M.E., Garcia-Sanz R., Marin L., et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood 112 (2008) 2709
43. Iizuka T., Miller S.C., and Marks Jr. S.C. Alveolar bone remodeling after tooth extraction in normal and osteopetrotic (ia) rats. J Oral Pathol Med 21 (1992) 150
44. Wang H.L., Weber D., and McCauley L.K. Effect of long-term oral bisphosphonates on implant wound healing: Literature review and a case report. J Periodontol 78 (2007) 584
45. Lam D.K., Sandor G.K., Holmes H.I., et al. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 73 (2007) 417
46. Lam D.K., Sandor G.K., Holmes H.I., et al. Marble bone disease: A review of osteopetrosis and its oral health implications for dentists. J Can Dent Assoc 73 (2007) 839
47. Bertoldo F., Santini D., and Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: A pathogenic puzzle. Nat Clin Pract 4 (2007) 711
48. Ruggiero S.L., and Woo S.B. Bisphosphonate-related osteonecrosis of the jaws. Dent Clin North Am 52 (2008) 111
49. Landesberg R., Cozin M., Cremers S., et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66 (2008) 839
50. Woo S.B., and Kalmar J.R. Osteonecrosis of the jaws and bisphosphonates. Alpha Omegan 100 (2007) 194
51. Komatsubara S., Mori S., Mashiba T., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19 (2004) 999
52. Mashiba T. [Assessment of bone quality: Bone quality and osteoporosis treatment]. Clin Calcium 18 (2008) 300
53. Mashiba T., Mori S., Burr D.B., et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metabol 23 suppl (2005) 36
54. Reid I.R., Bolland M.J., and Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41 (2007) 318
55. Demerjian N., Bolla G., and Spreux A. Severe oral ulcerations induced by alendronate. Clin Rheumatol 18 (1999) 349
56. Treister N.S., Richardson P., Schlossman R., et al. Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105 (2008) e1
57. Schenk R., Eggli P., Fleisch H., et al. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38 (1986) 342
58. Adami S., and Zamberlan N. Adverse effects of bisphosphonates: A comparative review. Drug Saf 14 (1996) 158
59. Whyte M.P., McAlister W.H., Novack D.V., et al. Bisphosphonate-induced osteopetrosis: Novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res 23 (2008) 1698
60. Whyte M.P., Wenkert D., Clements K.L., et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 349 (2003) 457
61. Allegra A., Oteri G., Nastro E., et al. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 25 (2007) 164
62. Santini D., Vincenzi B., Avvisati G., et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8 (2002) 1080
63. Santini D., Schiavon G., Angeletti S., et al. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: A new role for these drugs?. Recent Patents on Anti-Cancer Drug Discovery 1 (2006) 383
64. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567
65. Weitzman R., Sauter N., Eriksen E.F., et al. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62 (2007) 148
66. Nastro E., Musolino C., Allegra A., et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 117 (2007) 181
67. Krueger C.D., West P.M., Sargent M., et al. Bisphosphonate-induced osteonecrosis of the jaw. Ann Pharmacother 41 (2007) 276
68. Magopoulos C., Karakinaris G., Telioudis Z., et al. Osteonecrosis of the jaws due to bisphosphonate use: A review of 60 cases and treatment proposals. Am J Otolaryngol 28 (2007) 158
69. Migliorati C.A., Casiglia J., Epstein J., et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc 136 (2005) 1658
70. Mignogna M.D., Fedele S., Lo Russo L., et al. Case 2: Osteonecrosis of the jaws associated with bisphosphonate therapy. J Clin Oncol 24 (2006) 1475
71. Shimura K., Shimazaki C., Taniguchi K., et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 84 (2006) 343
72. Soileau K.M. Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol 77 (2006) 738
73. Kumar S.K., Meru M., and Sedghizadeh P.P. Osteonecrosis of the jaws secondary to bisphosphonate therapy: A case series. J Contemp Dent Pract 9 (2008) 63
74. Lee C.Y., David T., and Nishime M. Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: A report of 2 cases. J Oral Implantol 33 (2007) 371
75. Allen B.W., Demchenko I.T., and Piantadosi C.A. Two faces of nitric oxide: implications for cellular mechanisms of oxygen toxicity. J Appl Physiol 106 (2009) 662
76. 2 concentration in rat brain after hyperoxic convulsions. J Appl Physiol 69 (1990) 1761
77. Demchenko I.T., Boso A.E., O'Neill T.J., et al. Nitric oxide and cerebral blood flow responses to hyperbaric oxygen. J Appl Physiol 88 (2000) 1381
78. Demchenko I.T., Boso A.E., Whorton A.R., et al. Nitric oxide production is enhanced in rat brain before oxygen-induced convulsions. Brain Res 917 (2001) 253
79. Reddy S.V. Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Expr 14 (2004) 255
80. van't Hof R.J., and Ralston S.H. Nitric oxide and bone. Immunology 103 (2001) 255
81. Khosla S. Minireview: The OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050
82. Yu X.H., Yang Y.J., Wang X., et al. [Effect of hyperbaric oxygenation on neural stem cells and myelin in neonatal rats with hypoxic-ischemic brain damage.]. Zhongguo Dang Dai Er Ke Za Zhi 8 (2006) 33
83. Liu Z.J., and Velazquez O.C. Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing. Antioxid Redox Signal 10 (2008) 1869
84. Fok T.C., Jan A., Peel S.A., et al. Hyperbaric oxygen results in increased vascular endothelial growth factor (VEGF) protein expression in rabbit calvarial critical-sized defects. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105 (2008) 417
85. Lee C.C., Chen S.C., Tsai S.C., et al. Hyperbaric oxygen induces VEGF expression through ERK, JNK and c-Jun/AP-1 activation in human umbilical vein endothelial cells. J Biomed Sci 13 (2006) 143
86. Peng Z., Ren P., Kang Z., et al. Up-regulated HIF-1alpha is involved in the hypoxic tolerance induced by hyperbaric oxygen preconditioning. Brain Res 1212 (2008) 71
87. Li Z., Liu W., Kang Z., et al. Mechanism of hyperbaric oxygen preconditioning in neonatal hypoxia-ischemia rat model. Brain Res 1196 (2008) 151
88. Yogaratnam J.Z., Laden G., Madden L.A., et al. Hyperbaric oxygen: A new drug in myocardial revascularization and protection?. Cardiovasc Revasc Med 7 (2006) 146
89. Bianchi S.D., Scoletta M., Cassione F.B., et al. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 (2007) 249
90. Ikeda F., Nishimura R., Matsubara T., et al. Activation of NFAT signal in vivo leads to osteopenia associated with increased osteoclastogenesis and bone-resorbing activity. J Immunol 177 (2006) 2384
91. Crotti T.N., Flannery M., Walsh N.C., et al. NFATc1 directly induces the human beta3 integrin gene in osteoclast differentiation. J Musculoskel Neuron Interact 5 (2005) 335
92. Crotti T.N., Sharma S.M., Fleming J.D., et al. PU.1 and NFATc1 mediate osteoclastic induction of the mouse beta3 integrin promoter. J Cell Physiol 215 (2008) 636
93. Tanaka S., Miyazaki T., Fukuda A., et al. Molecular mechanism of the life and death of the osteoclast. Ann NY Acad Sci 1068 (2006) 180
94. Koga T., Matsui Y., Asagiri M., et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med 11 (2005) 880
95. Levy B.M., and Nelms D.C. Migratory inhibition factor associated with chronic destructive periodontitis. J Dent Res 50 (1971) 505
96. Morimoto T., Nishihira J., and Kohgo T. Immunohistochemical localization of macrophage migration inhibitory factor (MIF) in human gingival tissue and its pathophysiological functions. Histochem Cell Biol 120 (2003) 293